Olokizumab

Olokizumab is an immunomodulator. It binds to interleukin 6.[1] Hence acting as an Anti-IL-6 therapeutic aimed at inflammatory disease e.g. rheumatoid arthritis (RA).

Olokizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetIL6
Clinical data
ATC code
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
 ☒NcheckY (what is this?)  (verify)

It had promising results in a phase II trial against placebo or tocilizumab for patients with moderate to severe whan.[2][3]

Olokizumab was approved for medical use in Russia. On May 21, 2020, the Russian Health Ministry approved brand name Artlegia (olokizumab).

Olokizumab (64 mg once) is used as emergence experimental cytokine storm COVID-19 complications treatment.[4]

In a 24-week, Phase 3, multicenter, placebo- and active-controlled trial, olokizumab (at a dose of 64 mg every 2 or 4 weeks) was superior to placebo and noninferior to adalimumab in producing a response at 12 weeks.[5]

References
  1. World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103" (PDF). WHO Drug Information.
  2. Walsh N (6 August 2014). "RheumShorts: IL-6 and RA, Life and Death, Surgery in Lupus".
  3. Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, et al. (September 2014). "Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study". Annals of the Rheumatic Diseases. 73 (9): 1607–1615. doi:10.1136/annrheumdis-2013-204760. PMC 4145439. PMID 24641941.
  4. Marrow A (8 October 2020). "Russia's R-Pharm retools arthritis drug for COVID-19 patients in clinical trial". Reuters.
  5. Smolen JS, Feist E, Fatenejad S, Grishin SA, Korneva EV, Nasonov EL, et al. (August 2022). "Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis". The New England Journal of Medicine. 387 (8): 715–726. doi:10.1056/NEJMoa2201302. PMID 36001712. S2CID 251809819.
  • "Olokizumab". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.